Jyothi I Tirumalasetty, MD
Allergy/Immunology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tirumalasetty’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C164641 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · Drexel University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$10,658
Medicare paid this office $10,658 for 40 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 20 | $2,864 | $87 |
| New patient visit (45+ min) | 18 | $2,585 | $144 |
| New patient visit (30+ min) | 14 | $1,372 | $98 |
Who their Medicare patients are
40 Original Medicare patients in 2024. Average age 72 · Women 68% · Health risk score 1.09. Above the middle of the specialty; the typical allergy/ immunology clinician is at 1.
Conditions among them: High blood pressure 53%.
The office billed $55,017, Medicare allowed $13,856 and paid $10,658; for 469 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 40 | 469 | 72 | 1.09 | $55,017 | $10,658 |
| 2022 | 32 | 158 | 65 | 1.90 | $30,493 | $3,247 |
| 2021 | 86 | 395 | 71 | 1.88 | $123,165 | $16,078 |
| 2020 | 47 | 272 | 69 | 1.63 | $62,197 | $11,032 |
| 2019 | 56 | 649 | 63 | 1.64 | $28,681 | $5,068 |
| 2018 | 52 | 555 | 60 | 1.87 | $28,379 | $5,786 |
| 2017 | 49 | 892 | 60 | 1.36 | $32,785 | $6,405 |
| 2016 | 49 | 979 | 59 | 1.30 | $31,279 | $6,586 |
| 2015 | 44 | 825 | 57 | 1.75 | $23,573 | $4,861 |
| 2014 | 49 | 779 | 58 | 1.52 | $26,775 | $6,633 |
| 2013 | 93 | 407 | 69 | 0.80 | $12,008 | $4,926 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2021: 4 services
| New patient visit (45+ min) | 35 | $4,697 | $134 |
| Return visit (30+ min) | 22 | $2,812 | $104 |
| New patient visit (30+ min) | 19 | $1,838 | $97 |
| Short return visit (20+ min) | 16 | $1,530 | $81 |
2020: 1 service
| New patient visit (30+ min) | 11 | $978 | $89 |
2019: 3 services
| Return visit (30+ min) | 15 | $1,475 | $61 |
| Short return visit (20+ min) | 19 | $959 | $36 |
| New patient visit (30+ min) | 15 | $859 | $57 |
2018: 2 services
| Return visit (30+ min) | 29 | $2,306 | $61 |
| New patient visit (30+ min) | 11 | $661 | $60 |
2017: 3 services
| New patient visit (45+ min) | 13 | $1,122 | $86 |
| Short return visit (20+ min) | 17 | $863 | $39 |
| Return visit (30+ min) | 12 | $862 | $62 |
2016: 4 services
| Professional service for preparation and provision of 1 or more antigens | 11 | $1,943 | $3 |
| Short return visit (20+ min) | 16 | $864 | $41 |
| New patient visit (30+ min) | 14 | $800 | $57 |
| Return visit (30+ min) | 11 | $727 | $66 |
2015: 1 service
| Short return visit (20+ min) | 14 | $720 | $42 |
2014: 3 services
| Short return visit (20+ min) | 21 | $1,265 | $40 |
| Professional service for preparation and provision of 1 or more antigens | 11 | $1,226 | $3 |
| Return visit (30+ min) | 11 | $991 | $66 |
2013: 3 services
| Professional service for multiple injections of allergen | 57 | $941 | $6 |
| Short return visit (20+ min) | 12 | $635 | $42 |
| Short return visit (20+ min) | 12 | $497 | $41 |
Medicaid work
$514 in 2020
Medicaid paid $514 for 30 billed services this clinician did in 2020, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 30 | $514 |
| 2020 | 30 | 1 | 13 | $514 |
| 2019 | 799 | 4 | 17 | $74,776 |
| 2018 | 925 | 5 | 27 | $87,276 |
See the largest Medicaid services in earlier years
2019
| ANTIGEN THERAPY SERVICES | 157 | $41,839 |
| New patient visit (30+ min) | 89 | $13,066 |
| Return visit (30+ min) | 75 | $12,199 |
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 478 | $7,672 |
2018
| ANTIGEN THERAPY SERVICES | 276 | $61,086 |
| Return visit (30+ min) | 105 | $14,374 |
| Professional services for allergen immunotherapy not including provision of allergenic extracts; 2 or more injections | 509 | $8,038 |
| New patient visit (30+ min) | 20 | $2,911 |
| Short return visit (20+ min) | 15 | $866 |
Drugs they prescribed that Part D paid
$20,603
Pharmacies billed $20,603 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 87) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.
68 generic and 19 brand-name prescriptions · $20,603 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Azelastine | 25 | $607 | $24 |
| Fluticasone Propionate | 11 | $139 | $13 |
Year by year
| 2024 | 87 | 25 | 0% (0) | 22% | $20,603 |
| 2022 | 151 | 44 | 0% (0) | 28% | $69,975 |
| 2021 | 259 | 66 | 0% (0) | 29% | $157,772 |
| 2020 | 339 | 72 | 0% (0) | 32% | $149,020 |
| 2019 | 793 | 81 | 0% (0) | 28% | $286,355 |
| 2018 | 670 | 74 | 0% (0) | 30% | $250,475 |
| 2017 | 553 | 72 | 0% (0) | 36% | $202,659 |
| 2016 | 378 | 50 | None | 34% | $85,880 |
| 2015 | 360 | 51 | None | 35% | $95,544 |
| 2014 | 314 | 43 | 0% (0) | 47% | $70,174 |
| 2013 | 111 | 34 | 0% (0) | 67% | $23,865 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 5 drugs
| Dupixent | 11 | $39,245 | $3,568 |
| Azelastine | 30 | $1,616 | $54 |
| Hydroxyzine | 11 | $174 | $16 |
| Famotidine | 11 | $109 | $10 |
| Montelukast | 12 | $98 | $8 |
2021: 9 drugs
| Xolair | 23 | $74,239 | $3,228 |
| Dupixent | 13 | $44,559 | $3,428 |
| Azelastine | 28 | $807 | $29 |
| Ipratropium | 12 | $742 | $62 |
| Omeprazole | 21 | $350 | $17 |
| Fluticasone Propionate | 17 | $333 | $20 |
| Famotidine | 22 | $317 | $14 |
| Hydroxyzine | 29 | $186 | $6 |
| Levocetirizine Dihydrochloride | 11 | $147 | $13 |
2020: 8 drugs
| Xolair | 28 | $98,693 | $3,525 |
| Breo Ellipta | 15 | $5,680 | $379 |
| Incruse Ellipta | 14 | $5,091 | $364 |
| Epinephrine | 11 | $2,815 | $256 |
| Azelastine | 32 | $1,625 | $51 |
| Fluticasone Propionate | 50 | $853 | $17 |
| Montelukast | 54 | $767 | $14 |
| Levocetirizine Dihydrochloride | 29 | $684 | $24 |
2019: 18 drugs
| Xolair | 52 | $175,529 | $3,376 |
| Nucala | 15 | $46,136 | $3,076 |
| Incruse Ellipta | 19 | $6,470 | $341 |
| Advair Hfa | 12 | $5,215 | $435 |
| Spiriva Respimat | 11 | $5,144 | $468 |
| Breo Ellipta | 13 | $4,620 | $355 |
| Azelastine | 99 | $4,589 | $46 |
| Epinephrine | 12 | $2,883 | $240 |
| Montelukast | 150 | $2,396 | $16 |
| Arnuity Ellipta | 11 | $1,971 | $179 |
| Fluticasone Propionate | 73 | $1,529 | $21 |
| Fluticasone-Salmeterol | 11 | $1,261 | $115 |
| Ventolin Hfa | 18 | $1,138 | $63 |
| Levocetirizine Dihydrochloride | 86 | $1,035 | $12 |
| Ranitidine | 36 | $218 | $6 |
| Hydroxyzine | 16 | $169 | $11 |
| Omeprazole | 11 | $166 | $15 |
| Prednisone | 27 | $123 | $5 |
2018: 16 drugs
| Xolair | 51 | $191,283 | $3,751 |
| Advair Diskus | 33 | $18,885 | $572 |
| Symbicort | 21 | $6,684 | $318 |
| Spiriva Respimat | 11 | $4,529 | $412 |
| Flovent Diskus | 11 | $2,936 | $267 |
| Azelastine | 47 | $2,158 | $46 |
| Montelukast | 136 | $2,076 | $15 |
| Fluticasone Propionate | 97 | $1,589 | $16 |
| Ventolin Hfa | 22 | $1,339 | $61 |
| Fluticasone-Salmeterol | 11 | $635 | $58 |
| Levocetirizine Dihydrochloride | 62 | $623 | $10 |
| Ipratropium | 24 | $513 | $21 |
| Desloratadine | 12 | $185 | $15 |
| Ranitidine | 36 | $157 | $4 |
| Gabapentin | 12 | $112 | $9 |
| Prednisone | 13 | $98 | $8 |
2017: 12 drugs
| Xolair | 52 | $155,427 | $2,989 |
| Advair Diskus | 25 | $12,403 | $496 |
| Azelastine | 55 | $3,437 | $62 |
| Epinephrine | 12 | $3,133 | $261 |
| Flovent Diskus | 11 | $2,582 | $235 |
| Ventolin Hfa | 26 | $1,964 | $76 |
| Montelukast | 87 | $1,423 | $16 |
| Fluticasone Propionate | 100 | $1,376 | $14 |
| Proair Hfa | 17 | $998 | $59 |
| Levocetirizine Dihydrochloride | 34 | $362 | $11 |
| Ranitidine | 22 | $227 | $10 |
| Prednisone | 15 | $66 | $4 |
2016: 10 drugs
| Xolair | 12 | $50,715 | $4,226 |
| Epipen 2-Pak | 19 | $10,847 | $571 |
| Advair Diskus | 14 | $5,812 | $415 |
| Pataday | 12 | $2,284 | $190 |
| Fluticasone Propionate | 90 | $1,451 | $16 |
| Montelukast | 80 | $1,394 | $17 |
| Ventolin Hfa | 12 | $1,158 | $96 |
| Azelastine | 31 | $809 | $26 |
| Ipratropium | 12 | $209 | $17 |
| Ranitidine | 17 | $196 | $12 |
2015: 8 drugs
| Xolair | 11 | $62,855 | $5,714 |
| Advair Diskus | 15 | $7,987 | $532 |
| Epipen 2-Pak | 11 | $5,360 | $487 |
| Montelukast | 85 | $1,587 | $19 |
| Azelastine | 29 | $1,426 | $49 |
| Fluticasone Propionate | 76 | $1,210 | $16 |
| Proair Hfa | 22 | $1,147 | $52 |
| Desloratadine | 13 | $517 | $40 |
2014: 8 drugs
| Xolair | 15 | $37,128 | $2,475 |
| Advair Diskus | 32 | $13,593 | $425 |
| Symbicort | 14 | $4,383 | $313 |
| Proair Hfa | 24 | $1,203 | $50 |
| Azelastine | 17 | $1,177 | $69 |
| Fluticasone Propionate | 49 | $1,114 | $23 |
| Montelukast | 59 | $1,040 | $18 |
| Ventolin Hfa | 11 | $849 | $77 |
2013: 2 drugs
| Advair Diskus | 16 | $5,712 | $357 |
| Montelukast | 11 | $549 | $50 |
Money from drug and device companies
$245 in 2025
| 2025 | 2 | 3 | None | $245 |
| 2024 | 1 | 1 | None | $31 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Wayrilz | $191 | 2 payments
|
| Genentech USA | Xolair | $54 | 1 payment
|
See all 3 published payments
| Genentech USA | Meals · 2025-05-20 | Xolair | $54 |
| Genzyme | Meals · 2025-05-20 | None | $82 |
| Genzyme | Meals · 2025-05-20 | Wayrilz | $109 |
See earlier years (2024)
2024: $31
| Novartis Pharmaceuticals | None | $31 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1942257605
- Licence
- CA C164641California C164641: Current · expires 2027-08-31
- Trained
- Drexel University College of Medicine, 2001
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207K00000X (207K00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-05-28
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.